ClinicalTrials.gg
Not yet recruitingNCT07628985Updated Jun 5, 2026

BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes

A Phase 3 interventional study of Bofanglutide and Semaglutide in Type 2 Diabetes Mellitus (T2DM), sponsored by Carnot Laboratories. Not yet recruiting at 7 sites in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Carnot Laboratories · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
374
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing bofanglutide in Diabetes Mellitus, Type 2 — 2 open to participants now, 5 under way, 1 of them phase 3. bofanglutide · Diabetes Mellitus, Type 2.

Planned enrollment
2nd of 10
374 · median 91
Started
2026
the only one that year
Phase 3
3 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Carnot Laboratories

Among the 10 studies testing bofanglutide in Diabetes Mellitus, Type 2, this one is the 2nd largest by planned enrollment, is the only one that started in 2026, is one of 3 in phase 3, and was the 10th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 10 studies testing bofanglutide in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About bofanglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing bofanglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with type 2 diabetes mellitus who have inadequate glycemic control while receiving stable metformin monotherapy. The main questions it aims to answer are:

Does Bofanglutide (GZR18) provide glycemic control comparable to Semaglutide based on changes in HbA1c? Is Bofanglutide (GZR18) safe and well tolerated in the study population? Can participants achieve glycemic targets and improve metabolic outcomes during treatment?

Researchers will compare participants receiving Bofanglutide (GZR18) with participants receiving Semaglutide to evaluate their effects on glycemic control, metabolic outcomes, safety, quality of life, and treatment satisfaction.

Participants will:

Be randomly assigned in a 1:1 ratio to receive Bofanglutide (GZR18) or Semaglutide.

Continue stable metformin monotherapy during the study. Receive subcutaneous study treatment with dose escalation according to the study protocol.

Participate in 30 weeks of active treatment. Attend scheduled study visits, laboratory assessments, and safety evaluations. Complete questionnaires related to quality of life and treatment satisfaction.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years and older who agree to participate in the study by voluntarily signing the Form.
  • Adult participants of either male or female sex.
  • Diagnosis of type 2 diabetes mellitus (T2DM) with a duration greater than 6 months, established according to the diagnostic and classification criteria for diabetes mellitus of the World Health Organization (WHO) in 1999, as well as the supplementary WHO diagnostic criteria of 2011, and in accordance with the widely accepted clinical criteria of the American Diabetes Association.
  • Background treatment with metformin monotherapy, at a stable dose for at least 90 days prior to screening, at a dose ≥1500 mg/day or at the maximum tolerated dose (MTD; ≥1000 mg/day), with no planned changes during the study.
  • determined by central laboratory during the screening period ≥7.0% and ≤10.5%.
  • Fasting plasma glucose (FPG) during screening \<270 mg/dL.
  • (BMI) ≥27 kg/m².
  • Stable body weight prior to screening, defined as a change ≤5% in body weight during the previous 3 months.
  • Women of must have a negative pregnancy test during screening and at the baseline visit; must not be breastfeeding; must have no plans for pregnancy from signing the ICF until 6 months after the last dose of study treatment; and must agree to use effective methods during this period.

Men must have no plans for sperm donation during the same period.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to GLP-1 type drugs or any of their ; or presence of for this type of medication.
  • Participation in clinical trials of other drugs or devices and having received treatment within the 3 months prior to the screening period.
  • Conditions that may cause significant instability in body weight or glycemic control within the 3 months prior to screening, including, but not limited to:

    • Major surgery or surgical procedures with the potential to significantly alter body weight, intake, absorption, gastric emptying, mobility, or metabolic recovery.
    • Current use of non-antidiabetic medications that affect body weight.
    • Participation in weight loss programs that are not in the maintenance phase.
  • Use, initiation, discontinuation, or relevant dose change of concomitant medications that, in the investigator's judgment, may significantly affect glycemic control or body weight, including, but not limited to, chronic systemic , antipsychotics, antiepileptics, or other drugs with relevant metabolic effects, within the 12 weeks prior to the screening period, or plans to initiate or modify such treatments during the study.
  • History of alcohol or drug abuse, including, but not limited to, amphetamines, benzodiazepines, marijuana, cocaine, methadone, and morphine-like drugs, within the 6 months prior to screening, determined by medical history or positive substance abuse screening test results (urine).
  • Previous antidiabetic treatment with:

    • Insulin for more than 14 consecutive days within the year prior to screening (insulin treatment for gestational diabetes mellitus is not considered under this criterion).
    • GLP-1 receptor agonists within the 6 months prior to screening.
    • DPP-4 inhibitors ≤3 months prior to screening.
  • Use of medications such as growth hormone, or others that, in the investigator's judgment, may affect insulin levels, within the 3 months prior to screening.
  • History of diabetic ketoacidosis, diabetic lactic acidosis, or hyperosmolar non-ketotic coma within the 6 months prior to screening.
  • T2DM complications such as proliferative retinopathy or maculopathy that is unstable or has required treatment; severe diabetic neuropathy, intermittent claudication, or diabetic foot within the 6 months prior to screening.
  • Severe hypoglycemia (Grade 3) within the 6 months prior to screening; or ≥3 episodes of hypoglycemia (blood glucose ≤70 mg/dL) within the month prior to screening; or recurrent symptoms related to hypoglycemia.
  • Severe trauma, serious infection, or major surgery that, in the investigator's judgment, may affect glycemic control, within the month prior to screening.
  • Serum calcitonin ≥50 pg/mL during screening.
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2A or 2B (MEN 2A/2B), or diagnosis of other malignant neoplasms within the last 5 years.
  • Uncontrolled hyperthyroidism or hypothyroidism. Subjects who have received stable thyroxine replacement treatment for ≥3 months prior to screening and whose TSH, FT3, and FT4 levels are within normal ranges are exempt from this criterion.
  • History of acute or chronic hepatitis, acute or chronic pancreatitis, symptomatic gallbladder disease (for example, multiple gallstones), pancreatic injury, or other high-risk factors that may predispose to the development of pancreatitis.
  • Uncontrolled arterial hypertension, defined as systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) ≥100 mmHg at screening.
  • History of hospitalization for severe cardiovascular disease (including, among others, acute myocardial infarction, unstable angina, cerebrovascular disease, or peripheral vascular disease) or sequelae of cerebrovascular disease within the 6 months prior to screening; presence of a cardiac pacemaker, second/third-degree atrioventricular block, long syndrome, QTc ≥450 ms on 12-lead without pacemaker; class III or IV heart failure; or any other cardiac abnormality that, in the investigator's judgment, makes the subject unsuitable for the study.
  • Clinically significant hematologic disorders or any condition that may affect erythrocyte half-life or stability, and therefore interfere with interpretation of (HbA1c), including, but not limited to, aplastic anemia, myelodysplastic syndrome, thalassemia, sickle cell anemia, hemolytic anemia, or any disease causing hemolysis or erythrocyte instability (including malaria or Henoch-Schönlein purpura). Likewise, blood donation or blood loss >400 mL or blood transfusion within the 3 months prior to screening.
  • Clinically significant gastric emptying abnormalities (for example, gastric outlet obstruction), severe chronic gastrointestinal disorders (for example, active ulcers within the last 6 months), prolonged use of drugs that directly affect gastrointestinal motility (including, but not limited to, domperidone, mosapride, cisapride), or gastrointestinal surgery within the 6 months prior to screening, which, in the investigator's judgment, make the subject unsuitable to participate in the study.
  • Clinically significant laboratory abnormalities, including:

    • or AST ≥2.5 times the (ULN).
    • Fasting triglycerides >500 mg/dL.
    • Amylase and/or lipase ≥1.5 times the ULN.
    • Fasting blood glucose >270 mg/dL.
    • Estimated (eGFR) \<45 mL/min/1.73 m².
  • Evidence of clinically relevant active infection at screening, defined as:

    • virus (HBV): positive surface antigen (HBsAg) accompanied by detectable viral load (HBV DNA above the laboratory lower limit of detection).
    • virus (HCV): positive antibodies with detectable viral load (HCV RNA above the laboratory lower limit of detection). Subjects with resolved infection (documented negative RNA) may be included.
    • (HIV): confirmed infection with clinical impact or unstable treatment that, in the investigator's judgment, may interfere with subject safety or study participation.
    • Treponema pallidum: positive serology confirmed as active infection by confirmatory tests.
  • History of organ transplantation, or acquired or congenital immune system disorders.
  • Previous history of psychiatric disorders such as schizophrenia, bipolar disorder, previous suicidal tendency, etc., or use of psychiatric medications that, in the investigator's judgment, may interfere with subject participation in the study or protocol compliance.
  • Any clinical condition or circumstance that, in the investigator's judgment, may compromise subject safety, protocol compliance, or the validity and interpretability of study data.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
374 participants (estimated)

Study arms

  • Experimental
    Arm 1: Bofanglutide (GZR18)

    Participants will receive Bofanglutide (GZR18) administered as a subcutaneous injection every two weeks with dose escalation according to the study protocol, while continuing stable metformin monotherapy.

    Biological: Bofanglutide

  • Active comparator
    Arm 2: Semaglutide

    Participants will receive Semaglutide administered as a weekly subcutaneous injection with dose escalation according to the study protocol, while continuing stable metformin monotherapy.

    Biological: Semaglutide

Interventions

  • BiologicalBofanglutide

    Long-acting GLP-1 receptor agonist administered as a subcutaneous injection every two weeks with dose escalation from 1.5 mg up to 18 mg according to the study protocol.

    Also known as: GZR18

  • BiologicalSemaglutide

    GLP-1 receptor agonist administered as a weekly subcutaneous injection with dose escalation from 0.25 mg up to 1 mg according to the study protocol.

06

What researchers measure

Primary outcomes

  1. Change in Hemoglobin A1c (HbA1c) From Baseline at Week 30

    Evaluation of the change in Hemoglobin A1c (HbA1c), expressed as percentage (%), from baseline to Week 30 during treatment

    Time frame: Baseline to Week 30

Secondary outcomes

  1. Proportion of Participants Achieving Glycemic Targets (HbA1c <7.0% and ≤6.5%) at Week 30

    To evaluate the proportion of participants achieving glycemic targets of HbA1c \<7.0% and ≤6.5% at Week 30 following treatment with Bofanglutide (GZR18) or Semaglutide.

    Time frame: Baseline to Week 30

  2. Change in Fasting Plasma Glucose From Baseline at Week 30

    Evaluation of the change in fasting plasma glucose concentration from baseline to Week 30 during treatment

    Time frame: Baseline to Week 30

  3. Change in Hemoglobin A1c (HbA1c) From Baseline at Week 16

    Evaluation of the change in Hemoglobin A1c (HbA1c) from baseline to Week 16 during treatment

    Time frame: Baseline to Week 16

  4. Change in Body Weight From Baseline at Week 30

    Evaluation of the change in body weight, expressed in kilograms (kg), from baseline to Week 30 during treatment.

    Time frame: Baseline to Week 30

  5. Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Total Score From Baseline at Week 33

    Evaluation of the change in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) total score from baseline to Week 30 during treatment

    Time frame: Baseline to Week 30

  6. Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) Total Score From Baseline at Week 30

    Evaluation of the change in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) total score from baseline to Week 30 during treatment

    Time frame: Baseline to Week 30

07

Study locations

7 sites
08

References and documents

Publications

  • Zhang M, Zhang Y, Peng X, He A, Wang Y, Deng Y, Cui C, Xue F, Wei B, Xing W, Qian Y, Mazuranic M, Chen W. GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models. Eur J Pharmacol. 2022 Aug 5;928:175107. doi: 10.1016/j.ejphar.2022.175107. Epub 2022 Jun 16. PubMed 35718129 ↗
  • Liu Y, Chen W, He X, He A, Zhao L, Xie T, Li Y, Zhao J, Hunt A, Shi A, Gan ZR. The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects. Diabetes Obes Metab. 2025 May;27(5):2777-2789. doi: 10.1111/dom.16285. Epub 2025 Mar 3. PubMed 40028667 ↗

Individual participant data

Plan to share: No — Individual participant data collected during the study will not be made available to other researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Oct 2027, 13 months later.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 13 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2026
First posted
Jun 5, 2026
StartEst.
Sep 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07628985
Lead sponsor
Carnot Laboratories
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Sep 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jun 5, 2026

Study contacts

Gisselle Vanessa González Hernández, MD
Contact
gvgonzalez@carnot.com
+52 5543705748
Sergio César Hernández Jiménez, Dr.
principal investigator · Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Centro de Atención Integral del Paciente con Diabetes (CAIPaDi)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bofanglutide

Start the discussion